Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bullish Setup | Bullish Swing Setup | 3.63% | |
| Multiple of Ten Bullish | Other | 3.63% | |
| Outside Day | Range Expansion | 3.63% | |
| Wide Bands | Range Expansion | 3.63% | |
| Gapped Up | Strength | 3.63% | |
| Multiple of Ten Bullish | Other | 6.28% | |
| Wide Bands | Range Expansion | 6.28% | |
| Overbought Stochastic | Strength | 6.28% | |
| Wide Bands | Range Expansion | 5.36% | |
| Overbought Stochastic | Strength | 5.36% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 5 minutes ago |
| Up 3% | 23 minutes ago |
| Gapped Up (Full) | about 1 hour ago |
| Bullish 180 Entry | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
Get a Trading Assistant
- Earnings date: 06/05/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 245.74 |
| 52 Week Low | 126.9681 |
| Average Volume | 193,879 |
| 200-Day Moving Average | 173.65 |
| 50-Day Moving Average | 154.97 |
| 20-Day Moving Average | 153.70 |
| 10-Day Moving Average | 162.93 |
| Average True Range | 5.53 |
| RSI (14) | 60.32 |
| ADX | 21.99 |
| +DI | 28.74 |
| -DI | 20.82 |
| Chandelier Exit (Long, 3 ATRs) | 152.78 |
| Chandelier Exit (Short, 3 ATRs) | 143.57 |
| Upper Bollinger Bands | 177.50 |
| Lower Bollinger Band | 129.90 |
| Percent B (%b) | 0.73 |
| BandWidth | 30.97 |
| MACD Line | 3.94 |
| MACD Signal Line | 2.80 |
| MACD Histogram | 1.1476 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 173.22 | ||||
| Resistance 3 (R3) | 172.42 | 168.85 | 171.83 | ||
| Resistance 2 (R2) | 168.85 | 166.72 | 169.25 | 171.37 | |
| Resistance 1 (R1) | 166.86 | 165.41 | 167.86 | 167.66 | 170.90 |
| Pivot Point | 163.29 | 163.29 | 163.78 | 163.69 | 163.29 |
| Support 1 (S1) | 161.30 | 161.16 | 162.30 | 162.10 | 158.86 |
| Support 2 (S2) | 157.73 | 159.85 | 158.13 | 158.39 | |
| Support 3 (S3) | 155.74 | 157.73 | 157.93 | ||
| Support 4 (S4) | 156.54 |
